Key facts
- Elastrin’s last known valuation is $32.0M (Nov 2023).
- It has raised $20.2M; the latest was Later Stage VC ($500K) in Mar 2025.
- Notable investors include SC Launch, Starbloom Capital, Kizoo Technology Capital, Lung, National Heart — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Elastrin
- ·The full record, as it builds
Funding rounds
No funding rounds for Elastrin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elastrin
Developer of biotech therapeutics designed to improve health by restoring damaged hardened tissue to healthy resilience. The company's therapeutics are focused on developing novel therapies by reversing the hardening of arteries and inflammatory tissue damage in arterial and lung disease models, enabling doctors to provide effective treatment of life-threatening diseases.
- Sector
- Healthcare
- HQ
- Greenville, SC, United States
- Founded
- 2017
- Employees
- 6
- Website
- elastrin.com/
- Ownership
- Privately Held (backing)
Elastrin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elastrin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elastrin in its N-PORT filings yet. We sweep new filings monthly.